samedan logo

 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Axol Bioscience introduces multi-electrode array screening services for human iPSC-derived cells

Axol Bioscience


• Expansion of Axol Bioscience’s service offering for pre-clinical drug discovery
• New services combine the Company’s iPSC-derived human cells and electrophysiological expertise with Axion Biosystems’ Maestro Pro MEA platform

Cambridge, UK, 13 October 2020: Axol Bioscience (Axol), a biotechnology company specializing in the use of stem cell technology to manufacture disease-relevant cell-based assay systems to the drug discovery industry, today announced the expansion of its service offering, with the introduction of multi-electrode array (MEA) screening for human induced pluripotent stem cell (hiPSC)-derived cells. The new services have been developed to support pre-clinical research by optimizing hiPSC-derived cell culture, while providing high-quality electrophysiological data acquisition and analysis from physiologically relevant human cell models.

As part of the new services, Axol is incorporating the Maestro Pro, a market-leading MEA platform from Axion Biosystems (Axion). This will allow customers to benefit from Axol’s extensive catalog of hiPSC-derived cells and in-house electrophysiology expertise, in combination with Axion’s most advanced offering. The Maestro Pro enables continuous label-free and real-time data acquisition and analysis from 768 electrodes, in up to a 96wp format, allowing for a high-throughput of data.

Axol’s MEA screening service offering will include:
• recording of field action potentials from neurons and cardiomyocytes
• local extracellular action potential (LEAP) and contractility recordings from cardiomyocytes
• cell visualization and multiplexing for microscopy and calcium imaging assays
• targeted panel compound and new chemical entity (NCE) screening
• cardiotoxicity and neurotoxicity testing
• cell, co-culture and disease model validation
• long-term cell proliferation studies
• bespoke projects and pilot studies.

The launch of Axol’s services follows the recent appointment of Liam Taylor as CEO at Axol, and forms part of the Company’s strategy to grow its iPSC technologies, products and services.

Liam Taylor, CEO, Axol Bioscience, said:“At Axol, we have worked extremely hard to establish ourselves as the market-leading provider of neuroscience and cardio-based hiPSC-derived cells. As we grow, it's now time to also offer our considerable in-house expertise to the preclinical drug discovery market. As such, we are proud to announce our new MEA capability utilizing the industry-leading Axion Maestro Pro platform.”

For further information about Axol’s MEA screening services, please visit: https://www.axolbio.com/page/mea-services
phone +44 (0)1223 751051
email support@axolbio.com
web https://www.axolbio.com/
email Suite 3, The Science Village, Chesterford Research Park, Little Chesterford, Cambridgeshire, CB10 1XL, United Kingdom
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Ready for Business: PPMA Show 2021

Countdown begins to first UK live event for the processing and packaging industry. In a few weeks’ time, PPMA Show 2021 will return to the NEC Exhibition Centre in Birmingham, from September 28th-30th. As the first major PPMA live event since September 2019, following the postponement of all live events in 2020 and early 2021 due to the COVID pandemic, exhibitors and visitors are getting ready to do face-to-face business. With a focus on supporting the processing and packaging communities with sustained business recovery following the challenges of the last year, PPMA Show 2021 will bring together over 250 exhibiting companies, offering businesses a long-overdue opportunity to see emerging technologies and explore the latest trends in the industry.
More info >>


White Papers

By Your Side for a Healthier World

West Pharmaceutical Services, Inc.

Every day, injectable drugs are administered to improve the lives of millions of patients around the world. And every day, West is working by your side to design and manufacture drug packaging and delivery systems that will bring our customers’ drugs from concept to the patient more efficiently, reliably and safely. West understands our customers’ challenges and helps with solutions every step of the way, with cutting-edge production technologies, an unmatched expertise in global regulatory compliance, and an ever-growing knowledge base of pharmaceutical drug product testing, development, packaging and delivery. Whether focused on one piece of the process or an end-to-end solution, West is by your side for a healthier world.
More info >>

Industry Events

Pharma Integrates 2021

16 November 2021, VIRTUAL CONFERENCE

Now in its tenth year, Pharma Integrates is a unique event bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement